FDA Approved Rucaparib for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
oncodaily - On December 17, 2025, the FDA issued a regular approval for rucaparib (Rubraca®), marking the formal conversion of its earlier accelerated authorization into full approval for BRCA-mutated metastatic castration-resistant prostate […]
AI Summary: The FDA has granted full approval to rucaparib (Rubraca®) for treating adults with BRCA‐mutated metastatic castration‐resistant prostate cancer, converting its prior accelerated approval into standard approval. This landmark decision offers a new treatment option for patients with this genetic profile.
Related Stories
FDA Lifts Hold on Intellia’s Phase 3 Gene Editing Trial / 5 months
FDA rejects Corcept’s cortisol modulator triggering setback / 6 months
FDA approves first gene therapy for Wiskott‐Aldrich syndrome / 6 months
FDA Approves Novartis’ Itvisma Gene Therapy for SMA Across Age Groups / 7 months
FDA Approves Ziftomenib for AML Treatment / 7 months
FDA updates Sarepta gene therapy label with severe warnings / 7 months
FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 7 wks
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try CDC, Pharmaceuticals, Clinical Trials, Hospital Operations and look for the RSS link.
StackHealth Time Machine